{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-24-002027","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2024-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.125056+00:00","generated_at":"2026-06-06T04:37:50.480456+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Gilead to acquire CymaBay for $4.3B, adding seladelpar for PBC with FDA priority review","bullets":["Gilead to pay $32.50/share in cash, total equity value of $4.3 billion, a 27% premium over CymaBay's Feb 9 close.","Seladelpar (PPARδ agonist) for primary biliary cholangitis has FDA priority review; PDUFA date Aug 14, 2024.","Phase 3 RESPONSE trial: seladelpar achieved primary composite endpoint (61.7% biochemical response vs 20% placebo).","Deal expected to close in Q1 2024, subject to HSR clearance and majority tender; termination fee of $151.6M.","Upon FDA approval, transaction expected to be ~neutral to Gilead EPS in 2025 and significantly accretive thereafter."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-24-002027","json":"https://secwatch.observer/filing/0000950103-24-002027.json","markdown":"https://secwatch.observer/filing/0000950103-24-002027.md","text":"https://secwatch.observer/filing/0000950103-24-002027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000095010324002027/0000950103-24-002027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000095010324002027/dp206638_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T04:37:50.480456+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f736cd9a2f6b2079865c8537cd52943fce552af","claim":"GILEAD SCIENCES, INC. entered into Agreement and Plan of Merger with CymaBay Therapeutics, Inc. valued at $32.50 per Share (effective 2024-02-11).","evidence_excerpt":"On February 11, 2024, Gilead Sciences, Inc., a Delaware corporation (\" Parent \" or \" Gilead \"), entered into an Agreement and Plan of Merger (the \" Merger Agreement \"), among Parent, CymaBay Therapeutics, Inc., a Delaware corporation (the \" Company \"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (\" Purchaser \").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882095/000095010324002027/0000950103-24-002027-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"CymaBay Therapeutics, Inc."},{"label":"Value","value":"$32.50 per Share"},{"label":"Effective","value":"2024-02-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}